Turk J Haematol 2015 Aug 6

Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.

Bektas O1, Uner A, Eliacik E, Uz B, Işık A, Etgul S, Bozkurt S, Haznedaroğlu IC, Goker H, Sayinalp N, Aksu S, Demiroglu H, Ozcebe OI, Buyukasik Y.
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disease. Patients are at risk for developing cytopenias or progression to acute myeloid leukemia. Different classification and prognostic scoring systems have been developed. The aim of this study was to compare the different prognostic scoring systems.
l="OBJECTIVES" NlmCategory="OBJECTIVE">Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disease. Patients are at risk for developing cytopenias or progression to acute myeloid leukemia. Different classification and prognostic scoring systems have been developed. The aim of this study was to compare the different prognostic scoring systems.

PATIENTS AND METHODS:

One hundred and one patients who were diagnosed with primary MDS during 2003-2011 in a tertiary care university hospital Hematology department were included in the study.

RESULTS AND CONCLUSIONS:

While IPSS, WPSS, MPSS and IPSS-R risk categories increased, leukemia free survival and overall survival decreased (p<0.001). When IPSS, WPSS, MPSS and IPSS-R prognostic systems were compared by Cox regression analysis WPSS was the best in predicting leukemia-free survival (p<.001), and WPSS (<.001) and IPSS-R (p = 0.037) were better in predicting overall survival.